Precision BioSciences (NASDAQ:DTIL) Upgraded at BMO Capital Markets

BMO Capital Markets upgraded shares of Precision BioSciences (NASDAQ:DTIL) from a market perform rating to an outperform rating in a report released on Friday, Marketbeat Ratings reports. The firm currently has $34.00 price target on the stock.

Precision BioSciences Price Performance

Shares of NASDAQ:DTIL opened at $5.70 on Friday. Precision BioSciences has a one year low of $3.61 and a one year high of $19.43. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The firm has a market capitalization of $43.72 million, a price-to-earnings ratio of 95.02 and a beta of 1.41. The company’s fifty day moving average price is $6.09 and its 200-day moving average price is $8.25.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Precision BioSciences stock. Janus Henderson Group PLC boosted its holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 702,069 shares of the company’s stock after purchasing an additional 68,943 shares during the period. Janus Henderson Group PLC owned approximately 9.15% of Precision BioSciences worth $6,322,000 at the end of the most recent reporting period. 37.99% of the stock is owned by hedge funds and other institutional investors.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.